Incidence of local recurrence in relation to radiotherapy and trastuzumab in early Her2 positive breast cancer

被引：0
|
作者：
Traa, F. [1 ]
Vane, M. [1 ]
Van Roozendaal, L. [2 ]
Heuts, E. [1 ]
Siesling, S. [3 ]
Moossdorff, M. [2 ]
Smidt, M. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, Surg, Maastricht, Netherlands
[2] Zuyderland Med Ctr, Surg, Heerlen, Netherlands
[3] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Hlth Technol & Serv Res, Enschede, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
368 (PB-16
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [1] Evaluating Trastuzumab in the treatment of HER2 positive breast cancer
    Jaques, Ryan
    Xu, Sam
    Matsakas, Antonios
    HISTOLOGY AND HISTOPATHOLOGY, 2020, 35 (10) : 1059 - 1075
  • [2] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    Lluch-Gomez, J.
    Nunez-Alvarez, V.
    de la Torre-Hita, C.
    Bernal-Gomez, M.
    Campini-Bermejo, A.
    Perdomo-Zaldivar, E.
    Rodriguez-Perez, L.
    Calvete-Candenas, J.
    Martinez-Bautista, M. J.
    Benitez-Rodriguez, E.
    Baena-Canada, J. M.
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [3] POPULATION BASED OUTCOME OF HER2 POSITIVE EARLY BREAST CANCER IN TRASTUZUMAB ERA
    Matos, E.
    Kuhar, C. Grasic
    Zakotnik, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 112 - 113
  • [4] Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients
    Hiroyasu Yamshiro
    Hiroji Iwata
    Norikazu Masuda
    Naohito Yamamoto
    Reiki Nishimura
    Shoichiro Ohtani
    Nobuaki Sato
    Masato Takahashi
    Takako Kamio
    Kosuke Yamazaki
    Tsuyoshi Saito
    Makoto Kato
    Tecchuu Lee
    Shinji Ohno
    Katsumasa Kuroi
    Toshimi Takano
    Masahiro Takada
    Shinji Yasuno
    Satoshi Morita
    Masakazu Toi
    International Journal of Clinical Oncology, 2015, 20 : 723 - 724
  • [5] Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
    J. Lluch-Gómez
    V. Núñez-Álvarez
    C. de la Torre-Hita
    M. Bernal-Gómez
    A. Campini-Bermejo
    E. Perdomo-Zaldívar
    L. Rodríguez-Pérez
    J. Calvete-Candenas
    M. J. Martínez-Bautista
    E. Benítez-Rodríguez
    J. M. Baena-Cañada
    Scientific Reports, 13
  • [6] PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer
    Earl, H. M.
    Cameron, D. A.
    Miles, D.
    Wardley, A. M.
    Ogburn, E. R. M.
    Vallier, A-L
    Loi, S.
    Higgins, H. B.
    Hiller, L.
    Dunn, J. A.
    CANCER RESEARCH, 2012, 72
  • [7] TRASTUZUMAB IN HER2 POSITIVE EARLY BREAST CANCER: A RETROSPECTIVE AUDIT IN A REGIONAL CANCER CENTER
    Heng, Sharon
    Pokharel, Khageshwor
    Gilbar, Peter
    Tannock, Margot
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 153 - 153
  • [8] Investigating the Role of HER4 in Relation to Trastuzumab Treatment and Resistance in HER2 Positive Breast Cancer
    Nafi, S. Mohd
    Kong, A.
    Gijsen, M.
    Kramer-Marek, G.
    Capala, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 126 - 126
  • [9] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [10] Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
    Gleeson, Jack Patrick
    Keegan, Niamh M.
    Morris, Patrick G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (03) : 251 - 262
12345